Dasatinib & Quercetin with CAR-T Cell Therapy
DART: Phase II Study of Dasatinib and Quercetin in Patients With Relapsed, Refractory Multiple Myeloma Receiving CAR-T Therapy
More Information
- Trial Status
- Accepting patients
- Trial Phase
- Phase 2
- Enrollment
- 44 patients (estimated)
- Sponsors
- Mayo Clinic
- Collaborators
- National Cancer Institute (NCI)
- Tags
- CAR T Cell, Kinase Inhibitor, Tyrosine Kinase (TK) Inhibitor
- Trial Type
- Treatment
- Last Update
- 1 month ago
- SparkCures ID
- 2113
- NCT Identifier
- NCT06940297
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print a patient-friendly report to share with your patient.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.